Physician profile
John Walter Escolas
NPI 1386856698
$26,354.32
in general payments reported to CMS, 2019-2025
77 companies · $2,727 in 2025
The $2,727 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,527 · 2020: $3,279 · 2021: $4,259 · 2022: $6,353 · 2023: $4,469 · 2024: $1,741 · 2025: $2,727.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,937.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,937.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $6,029.35 | 2019-2025 | |
| Glaxosmithkline, LLC. | $1,890.49 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $1,876.09 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $1,757.53 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Pfizer INC. | $1,360.87 | 2019-2025 | |
| Lilly USA, LLC | $1,244.89 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Janssen Pharmaceuticals, INC | $999.79 | 2019-2025 | Spravato, Xarelto |
| Amgen INC. | $965.22 | 2019-2025 | Repatha, Otezla, Evenity |
| Novartis Pharmaceuticals Corporation | $857.52 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $706.00 | 2019-2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $587.68 | 2019-2025 | Eliquis, Camzyos |
| Merck Sharp & Dohme LLC | $566.08 | 2019-2025 | Verquvo, Belsomra, Gardasil 9 |
| Allergan, INC. | $542.03 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $485.37 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $477.42 | 2021-2025 |
Show all 77 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Escolas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.